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Abstract 
18F-Fluorodeoxyglucose (18F-FDG) positron emission tomography–computed tomography (PET/CT) is 
integral to the investigation and management of suspected or proven lung cancer (1) despite the non-
specific nature of the 18F-FDG, which is a glucose analogue. An improved understanding in tumour 
biology and advances in therapeutic options has driven the need to better characterise tumours, and 
predict and monitor treatment response to new targeted cancer therapies. Some of the cancer-related 
cellular processes being investigated include tumour proliferation, amino acid metabolism, tumour 
hypoxia and angiogenesis. The majority of tracers being used to evaluate these processes remain 
restricted to preclinical and clinical research. There are also certain receptors which are expressed by 
specific cancers which can then be targeted by peptides, e.g. neuroendocrine tumours express 
somatostatin receptors which have an affinity to somatostatin analogues such as DOTA-peptides. 
68Ga-DOTA-peptides have an established role in PET imaging, including imaging of carcinoid tumours, 
but these are not specific to lung lesions. 
Introduction 
Positron emission tomography-computed tomography (PET/CT) has revolutionised the understanding 
of disease by enabling the evaluation of disease-specific function at a molecular level. It is established 
in the characterisation, staging and assessment of response to treatment across a wide range of 
malignancies, alongside applications in neurological disease, infection and inflammation and cardiac 
disease. According to the LuCE report on lung cancer (2016) (2), lung cancer is the 4th commonest 
cancer in the European Union effecting more than 312,000 people every year. 18F-Fluorodeoxyglucose 
(18F-FDG) PET/CT is used to characterise indeterminate lung nodules, staging of lung cancer and to 
assess response to variety of treatment options (1).18F-FDG is a glucose analogue that enables 
assessment of glucose metabolism, with areas of increased uptake, reflecting areas of increased 
glycolytic activity. Although, cancers cells have a reliance on glucose to generate energy, manifesting 
as areas of increased tracer uptake, 18F-FDG uptake can also be seen in areas of infection and 
inflammation as well as in normal cells. As such, 18F-FDG is sensitive but not specific for the detection 
of cancer.  
A better and improved understanding of cancer biology has led to the development of novel 
radiopharmaceuticals which might help better characterise tumours and predict response to targeted 
cancer therapeutics, with the hope of improving the overall diagnostic accuracy of imaging in lung 
cancer.  
 
Proliferation in lung cancer 
Cellular proliferation, leading to an increase in the number of cells as a result of cell growth and 
multiplication, is one of the hallmarks of malignancy and can be imaged and quantified with 18F-
fluorothymidine (18F-FLT).  Thymidine kinase-1 (TK-1) is an enzyme which is upregulated during DNA 
synthesis and cellular growth (3, 4). Uptake of 18F-FLT correlates with the activity of TK-1, as it is 
phosphorylated to 3-fluorothymidine monophosphate by TK-1 and it is then trapped intracellularly 
but not incorporated into DNA (5). 
11C-thymidine was used initially, however, due to its short half-life of 20 minutes requiring a cyclotron 
on site for production and rapid metabolism, it is unsuitable for routine use. Thymidine tracers  show 
physiological uptake in bone marrow and liver, which hinders assessment of these organs (6).   
In comparison with 18F-FDG, 18F-FLT generally demonstrates a lower degree of tumoural uptake as it 
is only taken up in the cells that are in the S phase (Fig. 1) (7). Its accumulation in tumour cells directly 
correlates with histopathological Ki-67 expression in non-small cell lung cancer (NSCLC) (8, 9), thus 
making it is a more specific oncological tracer than 18F-FDG (Fig. 2). 
There is a small body of literature exploring the comparative accuracies of 18F-FLT and 18F-FDG. Buck 
et al. compared uptake in lung cancer (NSCLC, SCLC and metastases) and showed whilst 18F-FLT uptake 
was related exclusively to malignant tumours, 18F-FDG uptake was also seen in 4/8 benign lesions (10). 
The investigators also found that the sensitivity of 18F-FLT for nodal staging was poor (53%), but could 
be a suitable radiopharmaceutical for investigating brain metastases as there is little background 
physiological tracer accumulation in the brain (9). They also suggested that 18F-FLT may be the superior 
tracer for assessment of therapy response and outcome. 
In a similar study in 31 patients with NSCLC, Yang et al. reported that the sensitivities of 18F-FLT and 
18F-FDG for primary lesions were 74% and 94%, respectively (p=0.003) and 18F-FDG was more sensitive 
in regional nodal staging (11). Tian et al. studied dual tracer imaging of pulmonary nodules with 18F-
FLT and 18F-FDG in 55 patients and found the combination to be better than either tracer alone (12).  
The sensitivity and specificity of 18F-FLT were 68.75% and 76.92% and for 18F-FDG were 87.5% and 
58.97%, respectively. The combination of dual-tracer PET/CT improved the sensitivity and specificity 
up to 100% and 89.74%, respectively.  
Other trials evaluated response assessment with FLT alone. Sohn et al. studied gefitinib (an EGFR 
tyrosine kinase inhibitor) response in patients with advanced adenocarcinoma of the lung measuring 
changes in 18F-FLT uptake and found that activity on day 7 differed significantly between responders 
and non-responders (13). Trigonis et al. found, in patients with NSCLC treated with radiotherapy and 
imaged with 18F-FLT PET, that radiotherapy induced an early significant decrease in tracer uptake, after 
5-11 treatment fractions (14). 
It has been found that treatment with ADI-PEG20 (arginine deiminase formulated with polyethylene 
glycol) in ASS 1 (Argininosuccinate synthase) deficient bladder tumours showed a marked reduction 
in the intracellular levels of thymidine due to the reduction in the TK1 protein levels (15). Utilising 18F-
FLT to assess treatment response of NSCLC and mesothelioma with ADI-PEG20 in combination with 
cisplatin and pemetrexed is encouraging and has shown a significant decrease in tracer uptake at the 
end of treatment, consistent with human tumour xenograft studies of ADI-PEG20 and the known 
pharmacology of arginine depletion in ASS1-deficient tumours, suggesting that measuring changes in 
proliferation with FLT are likely to be more specific than non-specific downstream effects on 18F-FDG 
(16-18). 
Amino acid metabolism in lung cancer 
Malignant cells demonstrate an increase in cellular proliferation along with an increase in amino acid 
transport (carrier mediated transport processes) and protein metabolism. These processes can be 
imaged through radiolabelled amino acids such as 11C-methionine and 18F-tyrosine, which are essential 
amino acids (19).  
The cellular uptake of large neutral amino acids is mediated by Na+ independent L-type amino acid 
transporters (LAT). Currently, 4 isoforms of system L transporters have been identified: LAT1, LAT2, 
LAT3, and LAT4. LAT1 is widely expressed in lung cancer amongst other primary human tumours of 
various tissue origins (20). LAT1 is upregulated in malignant tumours, and its expression is associated 
with tumour proliferation.  
Unlike 18F-FDG, radiolabelled amino acids have almost no tracer uptake in normal brain and as 
oncological PET tracers, have been used predominantly in the assessment of brain tumours (21). 11C 
methionine may reduce the number of false-positive findings in inflammatory lung disorders as it is 
more specific for malignancy than 18F-FDG. Several papers, from countries with endemic infective and 
inflammatory lung disorders, have looked at the possible diagnostic contribution of 11C-methioinine 
PET in differentiating benign and malignant lung nodules (22) with both Kubota et al. (23) and Hsieh 
et al. (24) reporting that 11C-methionine is more specific and sensitive when compared to 18F-FDG.  
18F labelled O-(2-18F-fluoroethyl)-L-tyrosine (18F-FET) has shown results similar to those obtained with 
11C methionine in imaging brain tumours(25)  and also demonstrated superior of human solid gliomas 
compared with MRI as shown by use of stereotactic biopsy samples as a reference (26). A recent study 
by Pauleit et al. has showed that 18F-FDG PET, 18F-FET PET may allow a better distinction between 
tumours and inflammatory tissues in patients with squamous cell carcinomas (21)l-3-18F-α-methyl 
tyrosine (18F-FAMT) has been developed as a PET radiopharmaceutical for tumour amino acid imaging. 
18F-FAMT is almost exclusively transported by the LAT1, making it more specific for malignant tissue 
(20). Clinical studies have demonstrated that 18F-FAMT exhibits higher cancer specificity in peripheral 
organs than other amino acid PET tracers and 18F-FDG. Kaira et al. showed that metabolic response 
on 18F-FAMT PET was a significant independent prognostic factor and could be a potential parameter 
to predict the prognosis after first-line chemotherapy in patients with advanced lung cancer (20). 
Hypoxia in lung cancer 
Tumour response to treatment has been shown to be significantly influenced by tumour hypoxia and 
oxygen metabolism. Intra-tumoral hypoxia increases radio-resistance and chemo-resistance, requiring 
an increase of 2.5–3 times the radiotherapy dose to achieve the same biological effect (27). It is also 
associated with poor clinical outcomes in solid tumours, including lung cancer (28-31).  
18F-fluoromisonidazole (18F-FMISO), initially used in nuclear cardiology to assess myocardial ischaemia, 
was the first PET radiopharmaceutical introduced into oncological imaging armamentarium to 
measure tumour oxygenation in several cancer types including lung cancer (Fig. 3), sarcomas, brain 
tumours and head and neck cancers (32, 33). 18F-FMISO enters cells by passive diffusion and is thought 
to undergo metabolism similar to MISO, being reduced by nitroreductase enzymes to form reduction 
products. These then bind to intracellular macromolecules when the oxygen tension is less than 10 
mmHg and is then trapped intracellularly (34, 35). 18F-FMISO is lipophilic and is excreted via the 
hepatobiliary route with pronounced liver and gut uptake. It does not accumulate in necrotic tissues, 
as the trapping process requires viable cells with functional nitroreductase enzymes (36). Limitations 
include slow tracer accumulation leading to low tumour-to-background contrast requiring delayed 
scans to allow background activity to decrease (37). Parameters used to quantify tumour hypoxia 
include tumour-to-blood uptake ratio (TBR) at 2 hours after injection using a cut off of 1.2 or 1.4 (38) 
(although TBR continues to increase up to 6 hours) (39) and standardised uptake value (SUV) and 
hypoxic fraction (HF, the fraction of pixels within the imaged tumour volume) (37).  
Several preclinical and clinical studies have shown moderate correlations between direct oxygen 
electrode measurements and uptake of 18F-FMISO. Clinical studies have shown 18F-FMISO selectivity 
in NSCLC but the mechanism for how radiotherapy affects intratumoural oxygenation status remains 
uncertain. So far, only very weak correlations have been demonstrated between 18F-FMISO and 18F-
FDG uptake and so further evaluation of the relationship between hypoxia and glucose metabolism is 
required (40-44). The feasibility of multi-tracer PET/CT scans performed in a short period of time prior 
to and during radiotherapy permits more sophisticated individualisation of NSCLC treatment. Further 
studies using larger cohorts and relating findings to patient outcomes are required (45). 
Development of further hypoxic tracers has been driven by the presence of a suboptimal signal-to-
background ratio of 18F-FMISO. These include 2- nitroimidazoles like 18F-fluoroazomycin arabinoside 
(18F-FAZA), which has a better TBR and is excreted via the renal route (46, 47). Studies have shown 
that uptake of 18F-FAZA and 18F-FDG differ in NSCLC, confirming that these tracers assess different 
intratumoural biological processes (37). Another hypoxia tracer is 18F-labeled 
fluoroerythronitroimidazole (18F-FETNIM). Clinical studies have shown the feasibility of 18F-FETNIM 
PET and its potential as a prognostic marker in NSCLC (37). 18F-3-fluoro-2-(4-((2-nitro-1H-imidazol-1-
yl) methyl)-1H-1,2,3-triazol-1-yl) propan-1-ol (18F-HX4) is an another 2-nitroimidazole analogue, 
which owing to its high-water solubility and fast clearance from the non-hypoxic tissues, gives a better 
TBR. In a recent study by Zeger et al. it showed considerable uptake in the majority of NSCLC patients 
in their study group (48). 
Alongside nitromidazole radiopharmaceuticals, the other most frequently used PET 
radiopharmaceutical is 64Cu-methylthiosemicarbazone (64Cu-ATSM). It is a neutral lipophilic molecule 
with a high cell membrane permeability and diffuses readily from the blood to surrounding cells. Once 
within the cell, it undergoes reduction only in hypoxic cells and becomes trapped intracellularly, but 
washes out rapidly from normal cells without any change (49). Copper has several positron-emitting 
radioisotopes which can be used. 64Cu, because of its long half-life of 12.7 hours, is  most frequently 
used and is suitable for long-distance distribution. 60Cu (t1/2 24 mins) and 62Cu (t1/2 9.7 mins), with short 
half-lives, allow serial imaging within a short time period to assess acute changes in hypoxia, e.g. due 
to therapeutic intervention. Due to conflicting correlative evidence with invasive oxygen 
measurements, the question as to whether Cu-ATSM is a true hypoxic imaging agent remains 
unanswered. The timing of image acquisition is important, as the initial phase of tracer uptake can be 
influenced by perfusion, whereas at later time points uptake is probably more indicative of tumour 
hypoxia, but later still may reflect trafficking of released copper following metabolism of the tracer. 
Clinical studies have shown that 64Cu-ATSM PET is feasible in NSCLC and may play a role as a prognostic 
marker (37, 49-52). 
Angiogenesis in lung cancer 
Angiogenesis is the complex biological process by which new blood vessels are formed and which has 
a vital role in the process of primary tumour growth, proliferation and metastasis. Angiogenesis is a 
highly-controlled process that is dependent on the intricate balance of numerous molecular pathways 
that involve several mediators, such as hypoxia-inducible factor 1 (HIF-1), matrix metalloproteinases 
(MMPs), αvβ3 integrin, E-selectin and growth factors/growth factor receptors, like vascular endothelial 
growth factor (VEGF), platelet-derived growth factor (PDGF) and fibroblast growth factor-2 (FGF-2), 
(53).  These pathways are important targets for cancer therapeutics and hence imaging(54). PET offers 
a number of methods to quantify the angiogenic process in tumours.  
Tumour blood flow can be measured using 15O-H2O, steady-state method described by Frackowiak et 
al., and the 15O-dynamic water method described by Lammertsma et al. (54).  
In association with tumour angiogenesis, integrins (a family of cell adhesion molecules), including αvβ3, 
are upregulated on activated endothelial cells. To date, most clinical studies have focused on targeted 
integrin PET imaging (1) of which αvβ3 integrin is the most extensively investigated imaging target in 
the integrin family. Integrin αvβ3 binds to a variety of extracellular matrix (ECM) molecules via the 
arginine-glycine-aspartic acid (RGD) sequence on ligands. The first generation RGD peptide tracers 
were mainly excreted by the hepatobiliary system, hence were associated with high background 
hepatobiliary and intestinal activity. In addition, the aspartic acid residue of RGD was found to be 
susceptible to degradation. Cyclisation and glycosylation of these cyclic RGD peptides further 
improved their pharmacokinetics. Second generation peptides, such as RGD-K5, are predominantly 
excreted by the kidneys with increased uptake and retention in tumours improving their imaging 
characteristics (55-59).  
RGD peptides can be labelled with 18F, 68Ga or 64Cu for PET imaging. Pre-clinical studies have confirmed 
that 18F-labelled RGD has good tumour specificity and is rapidly cleared via renal excretion (60, 61). 
Two of the most investigated monomeric RGD peptides are 18F-Galacto-RGD and 18F-Fluciclatide, 
(formerly known as AH111585).  
18F-Galacto-RGD PET uptake correlates with immunohistological staining of αvβ3 integrin. Beer et al. 
conducted a study comparing the SUVs of 18F-Galacto-RGD PET with 18F-FDG PET in NSCLC (n=10). 
Although no correlation was found, they suggested further evaluation of 18F-galacto-RGD PET for 
planning and response evaluation of targeted molecular therapies with antiangiogenic or αvβ3-
targeted drugs (62). Metz et al. performed a prospective study on 13 patients with primary or 
metastasised cancer (NSCLC, n = 9; others, n = 4), analysing the spatial relationship of αvβ3 expression, 
glucose metabolism and perfusion by PET and dynamic contrast-enhanced (DCE) MRI, focusing on 
tumour heterogeneity (63). This study found that regions with simultaneous high uptake of 18F-
Galacto-RGD and 18F-FDG also showed higher functional MRI perfusion parameters (gadopentetate 
dimeglumine concentration time curve (IAUGC), regional blood volume (rBV) and regional blood flow 
(rBF)), compared to areas with low uptake of both radiotracers. Concerning perfusion and αvβ3 
expression, their results showed a tendency toward higher values for all functional MRI parameters in 
areas with more intense 18F-galacto-RGD uptake than 18F-FDG. This was thought to be because glucose 
metabolism is upregulated in hypoxic cells (which may occur in poorly perfused tumours) (63).  
18F-Fluciclatide, binds to αvβ3 and αvβ5 integrins with high affinity and in a preclinical study was found 
to bind to Lewis lung carcinoma and Calu-6 NSCLC xenografts in mice, with favourable biodistribution 
properties that allow the non-invasive assessment of tumour vascularity and response to treatments 
that affect the tumour vascular compartment (61).   
Attempts at optimising the strategies in labelling peptides with 18F led to the development of 18F-
fluoride–aluminium complexes to radiolabel peptides such as 18F-AlF-NOTA-PRGD2 (18F-alfatide)  (64). 
18F-alfatide has shown promising imaging properties and pharmacokinetics that are comparable, or 
superior, to those of other monomeric and dimeric RGD peptides. In a pilot study, by Wan et al., 
including nine patients with lung cancer, 18F-Alfatide allowed identification of all tumours with SUVs 
of 2.9 ± 0.1 indicating a lower variance in tumour uptake than found by most other studies using RGD-
derivatives in patients (64). Another pilot study by Zhou et al. also suggested that 18F-Alfatide PET/CT 
potentially had a valuable role in the diagnosis of metastatic lymph nodes for NSCLC patients (65).  
Due to increasing availability, 64Cu and 68Ga have generated interest for labelling peptides, resulting in 
the introduction of a variety of radiopharmaceuticals labelled with these radionuclides. DOTA-
conjugated RGD peptide (DOTA-RGDyK) has been labelled with 64Cu (66). 68Ga NOTA-RGD is the first 
68Ga-labeled integrin-targeting compound for which initial clinical data is available. A study by Zheng 
et al. suggested that the diagnostic value of 68Ga-NOTA-PRGD2 for lung cancer diagnosis was 
comparable to 18F-FDG with a significant advantage over 18F-FDG in identifying metastatic lymph nodes 
with greater specificity (67).  
There is direct activation of the angiogenesis pathway by angiogenic factors, which include vascular 
endothelial growth factor (VEGF/VEGFR). The critical role of VEGF in cancer progression has been 
highlighted by the use of the humanised anti-VEGF monoclonal antibody bevacizumab (Avastin) for 
cancer treatment which has demonstrated a two-month survival benefit compared to doublet 
chemotherapy alone in advanced NSCLC (68).  However, no clinical studies using targeted PET or 
imaging of VEGF/VEGFR in lung cancer are available in the literature (1), although there is preclinical 
data showing the feasibility of VEGFR PET imaging, especially with radiolabelled specific antibodies. 
The extracellular matrix (ECM) also plays a role in neovascularisation. Matrix metalloproteinases 
(MMP) are proteolytic enzymes that degrade the basement membrane and ECM, facilitating 
endothelial cell migration during angiogenesis (54). MMP inhibitors have also been investigated as a 
therapeutic strategy in lung cancer. Marimastat, a synthetic MMP inhibitor, has been investigated in 
randomised controlled trials in stage III NSCLC and small cell lung cancer (SCLC), but failed to show any 
survival benefit with maintenance therapy. PET imaging using MMP-inhibitors has been investigated 
in the pre-clinical setting, although results from in vivo animal studies have not been promising (69-
71). 
Another pro-angiogenic factor in the ECM is fibronectin, which is involved in wound healing, cell 
migration and malignant transformation. The extra-domain B (ED-B) isoform of fibronectin localises 
to new vessels in a variety of proliferating solid animal tumour models including SCLC, as well as ocular 
angiogenesis and tumour healing. There are, however, no pre-clinical ED-B imaging studies in lung 
tumour models (37). 
Epidermal growth factor (EGFR) – Tyrosine kinase inhibitor (TKI) treatment strategies for NSCLC 
depend on the mutation status of EGFR (72). A recent study by Sun et al. demonstrated N-(3-chloro-
4-fluorophenyl)-7-(2-(2-(2-(2-18F-fluoroethoxy) ethoxy) ethoxy) ethoxy)-6-methoxyquinazolin-4-
amine (18F-MPG) PET/CT is a powerful method for precise quantification of EGFR-activating mutation 
status in NSCLC patients, and it is a promising strategy for noninvasively identifying patients sensitive 
to EGFR-TKIs and for monitoring the efficacy of EGFR-TKI therapy (72). 
Radiopharmaceuticals in Pulmonary Neuroendocrine Tumours  
18F-Dihydroxyphenylalanine (18F-DOPA) has been used as a PET radiopharmaceutical for in vivo 
imaging of the dopaminergic system in neurological disorders (73) since the 1980s. Later this 
radiopharmaceutical found use in the detection of malignancies such as brain tumours (74) and for 
detecting primary and metastatic disease of neuroendocrine differentiation (carcinoids, 
gastroenteropancreatic tumours, glomus tumours, medullary thyroid cancer, small cell lung cancer, 
and phaeochromocytoma) (75, 76). Neuroendocrine tumours (NETs) have been found to over produce 
an enzyme dihydrophenylalanine decarboxylase which metabolises 18F-DOPA (77). 18F-DOPA PET may 
be used to characterise pulmonary nodules with neuroendocrine components and to evaluate 
treatment response, but the literature is sparse (78, 79). 
NETs express somatostatin receptors (SSTRs) on their cell membrane and thus far, six SSTR subtypes 
have been described namely SSTR1, SSTR2A, SSTR2B, SSTR3, SSTR4 and SSTR5. The SSTR2 and SSTR5 
subtypes, in particular, are predominantly over-expressed on the cell membranes of NETs (on average 
in 80–90% of cases) whilst normal tissues express SSTR3 and SSTR5 subtypes (80). 68Ga has a 
favourable half-life of 68 minutes and is obtained from a generator which can last a number of months. 
68Ga-DOTA somatostatin analogues were developed for clinical purposes (81) with several 68Ga-DOTA-
peptides available for clinical use including; 68Ga-DOTA-Phe(1)-Tyr(3)-Octreotide (TOC), 68Ga-DOTA-
NaI(3)-Octreotide (NOC), and 68Ga-DOTA-Tyr(3)-Octreotate (TATE). The main difference among these 
three tracers (DOTA-TOC, DOTA-NOC, and DOTA-TATE) is their variable affinity to SSTR subtypes. All 
of them show a similar affinity for SSTR2 and 5, whereas 68Ga-DOTA-NOC demonstrates a high affinity 
for SSTR3 (82, 83). 68Ga-DOTA-peptides are reported to be excellent candidates for imaging and 
staging patients with NETs, including the localisation of primary tumours in patients with known NET 
metastases (carcinoma of unknown primary origin) (84, 85) with sensitivities and specificities of 97-
100% and 96-100%, respectively (86, 87) with a large series reporting a superior diagnostic accuracy 
to CT. 68-DOTA peptides can be used to characterise pulmonary nodules with a suspected 
neuroendocrine aetiology (Fig. 4, 5) (77). Kayani et al. reviewed cases of pulmonary NET who 
underwent both 68Ga-DOTATATE and 18F-FDG PET/CT and showed that typical bronchial carcinoids 
showed higher and more selective uptake of 68Ga-DOTATATE compared to 18F-FDG, whilst atypical 
carcinoids and higher grades demonstrated less 68Ga-DOTATATE uptake but were 18F-FDG-avid (88). 
In a recent prospective study by Walker et al. they investigated indeterminate pulmonary nodules 
(IPN) using both 68Ga-DOTATATE and 18F-FDG PET/CT. The found that both tracers had equivalent 
accuracy in the diagnosis of malignant nodules. 68Ga-DOTATATE was more specific (94% compared to 
81%) and less sensitive (73% compared to 93%) than 18F-FDG. Immunohistochemistry staining for 
SSTR2A receptor expression correlated with tumour stroma but not tumour cells (89). 
Radiopharmaceuticals in imaging programmed cell death-ligand (PD-L1) 
PD-L1 immune checkpoint inhibitors have changed the treatment options in advanced NSCLC which 
often demonstrate PD-L1 expression (90). There is a correlation between PD-L1 expression detected 
by immunohistochemistry and the response and progression free survival following PD-L1 monoclonal 
antibody treatment, such as nivolumab (91). Non-invasive quantification of PD-L1 expression in order 
to guide treatment is a current area of interest with some levels of success. A recent 13 patient trial 
by Niemeijer et al. (92) reported that in vivo imaging of the PD1/PD-L1 axis in NSCLC using 18F-BMS-
986192, an 18Fluor-labeled anti-PD-L1 Adectin and 89Zirconium-labeled nivolumab (89Zr-nivolumab), 
was feasible and safe in humans and could be used in PD-L1 expression quantification. There are other 
pre-clinical trials looking at different PD-L receptor expression (93).   
 
 Conclusions 
18F-FDG PET/CT, which assesses cellular glycolytic metabolism, has a very high sensitivity and has an 
established role in the management of lung malignancy. There are several other radiopharmaceuticals 
available to investigate different cellular and molecular processes in malignancy such as proliferation, 
amino acid metabolism, hypoxia and angiogenesis, which in turn improves characterisation of 
tumours and treatment response assessment. However, the use of these radiopharmaceuticals 
remains largely restricted to the research arena and are yet to be adopted into routine clinical practice. 
Radiopharmaceuticals used to evaluate NETs have an established role in clinical practice but their 
success is reliant upon sufficient SSTR expression on tumour cells. In vivo PD-L1 expression 
quantification in NSCLC using different radiotracers might be the key to unlock newer immune 
checkpoint inhibitor treatments. 
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Figure Legends 
 
Figure 1a:  
18F-FLT PET/CT: CT (lung windows) and fused PET/CT axial images shows FLT uptake in a left upper lobe 
lung nodule. Physiological uptake is present in the bone marrow. 
Figure 1b: 
18F-FDG PET/CT: CT (lung windows) and fused PET/CT axial image show the left upper lobe nodule is 
FDG avid, with greater uptake than the FLT scan.  
Figure 2:  
Post radiotherapy recurrent disease.  
18F-FDG PET/CT: CT (soft tissue windows), PET and fused PET/CT axial images (left) and 18F-FLT PET/CT 
PET and fused PET/CT axial images (right) 
The 18F-FLT study shows more focal uptake in the left anteromedial segment, with non-avid 
background consolidation.   
18F-FDG study shows heterogenous inflammatory FDG in left lower lobar consolidation with more 
intense uptake in the left anteromedial segment corresponding to recurrent tumour uptake also seen 
on the FLT scan.  
Figure 3: 
18F-FMISO PET/CT images 4 h p.i. on an SUV scale 0 – 3 for two different patients (courtesy and with 
permission McGowan DR, Macpherson RE, Hackett SL, Liu D, Gleeson FV, McKenna WG, et al. (18) F-
fluoromisonidazole uptake in advanced stage non-small cell lung cancer: A voxel-by-voxel PET kinetics 
study. Med Phys. 2017 Sep;44(9):4665-76). 
 
Figure 4a: 
18F-FDG PET/CT: CT (lung windows), PET and fused PET/CT axial image. A patient with a known 
neuroendocrine pancreatic tumour with a lung nodule. No significant FDG activity is present in keeping 
with low glycolytic activity in a well-differentiated tumour. 
Figure 4b: 
68Ga-Dotatate PET/CT: CT (lung windows), PET and fused PET/CT axial image. High uptake in the nodule 
is in keeping with a well-differentiated tumour with somatostatin receptor expression. 
Figure 5:  
68Ga-Dotatate PET/CT: axial image fused PET/CT, PET, CT (lung windows) and half body MIP showing 
an intensely avid well differentiated neuroendocrine tumour in the right upper lobe. 
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The role of new PET tracers for lung cancer 
Figure 1a:  
18F-FLT PET/CT: CT (lung windows) and fused PET/CT axial images 
Shows a FLT avid left upper lobe lung nodule. Physiological uptake in the bone marrow. 
 
 
Figure 1b: 
18F-FDG PET/CT: CT (lung windows) and fused PET/CT axial image 
Show the left upper lobe nodule is FDG avid.  
 
 
 
Figure 2:  
Post radiotherapy recurrent disease.  
18F-FDG PET/CT: CT(soft tissue windows), PET and fused PET/CT axial images along with 
18F-FLT PET/CT PET and fused PET/CT axial images 
 
 
 
 
 
 
 
 
 
 
 
 
18F-FDG study shows heterogenous 
FDG in left lower lobar consolidation 
with more intense uptake in the left 
anteromedial segment.  
18F-FLT study shows more focal FDG 
avidity in the left anteromedial 
segment, with non-avid background 
consolidation.   
Figure 3: 
18F-FMISO PET/CT images 4 h p.i. (pre-Buparlisib) on an SUV scale 0 – 3 for two different patients(1) 
 
 
 
 
 
1. McGowan DR, Macpherson RE, Hackett SL, Liu D, Gleeson FV, McKenna WG, et al. (18) F-
fluoromisonidazole uptake in advanced stage non-small cell lung cancer: A voxel-by-voxel PET 
kinetics study. Med Phys. 2017 Sep;44(9):4665-76. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4a: 
18F-FDG PET/CT: CT (lung windows), PET and fused PET/CT axial image. In a patient with known 
neuroendocrine pancreatic tumour with a lung nodule. 
 
 
 
 
 
 
Figure 4b: 
68Ga-Dotatate PET/CT: CT (lung windows), PET and fused PET/CT axial image. In patient with known 
neuroendocrine pancreatic tumour with a lung nodule. 
 
 
 
 
 
 
Figure 5:  
68Ga-Dotatate PET/CT: axial image fused PET/CT, PET,  CT (lung windows) and half body MIP showing 
an intensely avid neuroendocrine tumour in the right upper lobe. 
 
 
 
 
 
 
 
 
 
  
 
